MicroPort is a multinational medical technology company with headquarters in Shanghai; Irvine, California; and Clamart, France. The company designs and produces medical devices across multiple therapeutic areas including interventional cardiology, orthopedics, cardiac rhythm management, electrophysiology, neurovascular intervention, structural heart disease, surgical robotics, and critical care. MicroPort completed its initial public offering on the Hong Kong Stock Exchange in 2010 and has since established multiple specialized subsidiaries focused on distinct therapeutic areas, with several completing separate public listings. Recognized as one of the global Medtech Big 100 companies, MicroPort's coronary intervention products have been implanted in over 10 million patients globally since its founding, with devices distributed globally in over 90 countries across.
History
Founding and early coronary stent business (1998–2010) MicroPort was founded in 1998 in Shanghai by Zhaohua Chang and a team of engineers. The company initially focused on interventional cardiology devices, developing coronary balloons, catheters, and drug-eluting stents for the Chinese healthcare market. During the 2000s, MicroPort developed successive generations of drug-eluting stents, including the Firebird platform launched in 2004 and the Firebird2 platform that followed. By the end of the decade, the company had established itself as a leading domestic supplier of interventional cardiovascular devices in China with approximately 40% domestic market share. During this first decade, MicroPort also began expanding internationally with distribution into other Asian markets including Japan. In September 2010, MicroPort completed its initial public offering on the Hong Kong Stock Exchange (stock code: 00853.HK), raising capital to fund expansion of its product development pipeline and international operations. In 2014, MicroPort received regulatory approval in China for its Firehawk stent system, followed by a CE Mark in Europe in 2015. The Firehawk platform features a unique abluminal groove-filled design that delivers sirolimus using a biodegradable polymer, with a lower drug and polymer load compared to contemporary drug-eluting stents. Clinical outcomes were evaluated in the TARGET trial series, which demonstrated non-inferiority to conventional drug-eluting stents and superiority in certain clinical contexts. MicroPort also began development of Firesorb, a bioresorbable vascular scaffold, in the mid-2010s during a period when the broader industry was reassessing bioresorbable vascular scaffold technology as a whole. Following clinical setbacks with first-generation scaffolds, including Abbott's withdrawal of its Absorb device from global markets in 2017 and Boston Scientific's halt of its bioresorbable scaffold program the same year, MicroPort continued investment in a next-generation bioresorbable technology.
International expansion and acquisitions (2010s) Beginning in the 2010s, MicroPort pursued a diversification strategy, expanding from its core coronary intervention business into orthopedics, cardiac rhythm management (CRM), and endovascular therapies through a combination of organic development and strategic acquisitions in North America and Europe. In January 2014, MicroPort acquired Wright Medical's OrthoRecon business for approximately $290 million, establishing MicroPort Orthopedics with headquarters and manufacturing operations in Arlington, Tennessee. The acquisition included a portfolio of hip and knee reconstruction implants and positioned MicroPort among the top ten global orthopedic device manufacturers by revenue. MicroPort Orthopedics subsequently expanded operations into additional markets including India and other Asia-Pacific countries. MicroPort entered the CRM sector through a strategic collaboration with the Sorin Group announced in January 2014, establishing a joint venture focused on developing and commercializing CRM devices including pacemakers and implantable cardioverter-defibrillators. In April 2018, MicroPort acquired LivaNova's CRM business for approximately €190 million (US$230 million), consolidating its CRM operations with global headquarters and manufacturing facilities in Clamart, France. The acquisition included an established portfolio of pacemakers, defibrillators, and cardiac resynchronization therapy devices with regulatory approvals in Europe and other international markets. In May 2018, MicroPort acquired the operations of Lombard Medical Technologies, a UK-based manufacturer of endovascular stent-graft systems. The acquisition added established abdominal and thoracic aortic stent-graft platforms to MicroPort's vascular portfolio, including the Altura and Aorfix endovascular aneurysm repair systems, strengthening the company's position in the treatment of aortic disease. The acquired assets were integrated into MicroPort's endovascular business, which later became the separately listed subsidiary MicroPort Endovastec. In January 2019, MicroPort announced a commitment to invest approximately $398 million in France over several years to expand research, development, and manufacturing of CRM devices including pacemakers and defibrillators at its Clamart facility. The announcement was made at the "Choose France" investment summit at the Palace of Versailles, part of the French government's initiative to attract foreign direct investment in advanced manufacturing and medical technology. By the end of the decade, these acquisitions and investments had expanded MicroPort's operations from its original focus on coronary intervention into a diversified medical device company with business segments spanning orthopedics, cardiac rhythm management, and advanced endovascular therapies. The company's revenue composition reflected this diversification, with non-coronary segments representing a growing proportion of total revenue.
… excerpt ends here. Continue reading the full article.
